Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

NCT00836381 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Overactive Bladder

Interventions

DRUG: Tolterodine extended-release (ER) 4mg
DRUG: Placebo

Sponsor

Samsung Medical Center

Collaborators

[object Object]